141 related articles for article (PubMed ID: 31829460)
1. Iatrogenic Kaposi sarcoma in a patient treated with ruxolitinib: A case report.
Tourlaki A; Benzecry V; Veraldi S; Brambilla L
J Dermatol; 2020 Feb; 47(2):e38-e39. PubMed ID: 31829460
[No Abstract] [Full Text] [Related]
2. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib.
Omine T; Yamaguchi S; Yasumura R; Asakura Y; Takahashi K
J Dermatol; 2020 Apr; 47(4):e131-e132. PubMed ID: 32056237
[No Abstract] [Full Text] [Related]
3. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data.
Moutel M; Noel V; Jary A; Le QH; Lier C; Viguier M; Lebbe C; Azzouz B; Bani-Sadr F
Am J Hematol; 2022 Jan; 97(1):E31-E34. PubMed ID: 34724250
[No Abstract] [Full Text] [Related]
4. A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura.
Jerdan K; Brownell J; Singh M; Braniecki M; Chan L
Acta Oncol; 2017 Jan; 56(1):111-113. PubMed ID: 27885868
[No Abstract] [Full Text] [Related]
5. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Wysham NG; Sullivan DR; Allada G
Chest; 2013 May; 143(5):1478-1479. PubMed ID: 23648912
[TBL] [Abstract][Full Text] [Related]
6. Kaposi's sarcoma and other rare skin cancers in organ transplant patients.
Zattra E Coati I; Alaibac M; Piaserico S
G Ital Dermatol Venereol; 2014 Aug; 149(4):395-400. PubMed ID: 25068226
[TBL] [Abstract][Full Text] [Related]
7. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
8. [Kaposi sarcoma in cyclosporin A therapy of actinic reticuloid].
Waldmann V; Kempf W; Burg G; Dummer R
Hautarzt; 1997 Apr; 48(4):262-5. PubMed ID: 9206716
[TBL] [Abstract][Full Text] [Related]
9. Infections associated with ruxolitinib: study in the French Pharmacovigilance database.
Sylvine P; Thomas S; Pirayeh E;
Ann Hematol; 2018 May; 97(5):913-914. PubMed ID: 29340760
[No Abstract] [Full Text] [Related]
10. Ruxolitinib for myelofibrosis.
Haznedaroglu IC
N Engl J Med; 2012 May; 366(21):2032; author reply 2032-5. PubMed ID: 22621635
[No Abstract] [Full Text] [Related]
11. Ruxolitinib for myelofibrosis.
Koschmieder S; Koppelle A; Seifert H
N Engl J Med; 2012 May; 366(21):2031-2; author reply 2032-4. PubMed ID: 22621634
[No Abstract] [Full Text] [Related]
12. Ruxolitinib for myelofibrosis.
Diamantidis MD
N Engl J Med; 2012 May; 366(21):2031; author reply 2032-4. PubMed ID: 22621633
[No Abstract] [Full Text] [Related]
13. Kaposi's sarcoma post renal transplantation.
Pedagogos E; Nicholls K; Dowling J; Becker G
Aust N Z J Med; 1994 Dec; 24(6):722-3. PubMed ID: 7717927
[No Abstract] [Full Text] [Related]
14. Vegetating nodules following erosions on the oral cavity: a quiz. Iatrogenic Kaposi's sarcoma associated with pemphigus vulgaris.
Marzano AV; Recalcati S; Menicanti C; Crosti C; Cusini M
Acta Derm Venereol; 2015 Mar; 95(3):378-82. PubMed ID: 25111751
[No Abstract] [Full Text] [Related]
15. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibition in myelofibrosis.
Arellano-Rodrigo E; Alvarez-Larrán A
N Engl J Med; 2010 Dec; 363(25):2464; author reply 2464-5; discussion 2465. PubMed ID: 21158663
[No Abstract] [Full Text] [Related]
17. Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):990-992. PubMed ID: 29651917
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
20. Rapidly progressive Kaposi's Sarcoma in an Iraqi boy received Valproic acid: a case report and review of literature.
Al-Kzayer LF; Keizer P; Abdulraheem FT; Sano K; Kamata M; Sakashita K; Habbaba LA; Koike K
BMC Pediatr; 2016 Jul; 16():111. PubMed ID: 27459853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
